2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

Endocrine crises, complex coagulopathies, and perioperative immune reactions represent high-stakes anesthetic emergencies. The certified registered nurse anesthetist must maintain expert mastery over diabetic emergencies (DKA vs. HHS), thyroid storms, pheochromocytoma hemodynamic stabilization, stress-dose steroid protocols, cell-based coagulation cascades, heparin-induced thrombocytopenia (HIT), and life-saving management of perioperative anaphylaxis.

---

1. Diabetes Mellitus: DKA vs. HHS & Perioperative Glycemic Management

                               DIABETIC CRISES PATHOPHYSIOLOGY

               ABSOLUTE INSULIN DEFICIENCY                   RELATIVE INSULIN DEFICIENCY
               (Type 1 DM / Stress / SGLT2i)                 (Type 2 DM / Debilitated / Sepsis)
                           │                                             │
                           ▼                                             ▼
              DIABETIC KETOACIDOSIS (DKA)                  HYPEROSMOLAR HYPERGLYCEMIC STATE (HHS)
              • Rapid onset (<24 hours)                    • Insidious onset (days to weeks)
              • Marked Lipolysis (FFA release)             • Residual insulin blocks lipolysis (NO ketosis)
              • Hepatic Ketogenesis                        • Extreme Osmotic Diuresis
                (Beta-hydroxybutyrate & Acetoacetate)      • Massive Dehydration (8 - 10+ Liters)
              • High Anion Gap Metabolic Acidosis          • Hyperosmolality (>320 mOsm/kg)
              • Kussmaul respirations / Acetone breath     • Severe Hyperglycemia (>600 - 1,200+ mg/dL)
              • Moderate Fluid Deficit (3 - 6 Liters)      • Altered mental status / Seizures / Coma

Clinical & Laboratory Comparison: DKA vs. HHS

Management Protocols & Critical Potassium Rule

1. Intravenous Fluid Resuscitation:
   • Initial: 0.9% Normal Saline at $1.0\text{ to }1.5\text{ L/hr}$ (or $15-20\text{ mL/kg/hr}$) for the first 1-2 hours to restore effective circulating volume.
   • Subsequent: Switch to 0.45% NaCl if corrected serum sodium is normal or elevated.
   • Dextrose Addition: When serum glucose reaches $200-250\text{ mg/dL}$ in DKA (or $300\text{ mg/dL}$ in HHS), add 5% Dextrose (D5W or D5 1/2NS) to the infusion. This prevents hypoglycemia and rapid cerebral edema while allowing continuous IV insulin infusion to fully clear ketonemia and close the anion gap.
2. Insulin Therapy & The Potassium Rule:
   • The Cardinal Rule: NEVER administer insulin if serum potassium is $< 3.3\text{ mEq/L}$! Insulin drives potassium into cells via the $\text{Na}^+/\text{K}^+$-ATPase pump; giving insulin in severe hypokalemia triggers lethal ventricular arrhythmias, electromechanical dissociation, and respiratory muscle paralysis.
   • If $\text{K}^+ < 3.3\text{ mEq/L}$: Hold insulin; administer IV $\text{KCl}$ $20-30\text{ mEq/hr}$ until $\text{K}^+ > 3.3\text{ mEq/L}$.
   • If $\text{K}^+ 3.3\text{ to }5.3\text{ mEq/L}$: Administer regular insulin ($0.1\text{ units/kg}$ IV bolus, then $0.1\text{ units/kg/hr}$ infusion) and add $20-30\text{ mEq } \text{KCl}$ per liter of IV replacement fluid to maintain serum $\text{K}^+$ between $4.0-5.0\text{ mEq/L}$.
   • If $\text{K}^+ > 5.3\text{ mEq/L}$: Begin insulin infusion without potassium; monitor $\text{K}^+$ q1-2h.
3. SGLT2 Inhibitor Euglycemic DKA:
   • SGLT2 inhibitors (Empagliflozin, Dapagliflozin) promote glucosuria, lowering blood glucose while stimulating glucagon and lipolysis. Under perioperative stress, patients develop severe metabolic ketoacidosis with normal/near-normal blood glucose ($<200\text{ mg/dL}$). FDA Guidance: Discontinue SGLT2 inhibitors at least 3 to 4 days prior to elective surgery.
4. Perioperative Glycemic Target:
   • Maintain perioperative blood glucose between $140\text{ and }180\text{ mg/dL}$ ($7.8-10.0\text{ mmol/L}$). The NICE-SUGAR trial demonstrated that tight glycemic control ($80-110\text{ mg/dL}$) increases severe hypoglycemia and overall mortality.

---

2. Thyroid Emergencies: Thyroid Storm vs. Myxedema Coma

Thyroid Storm (Thyrotoxic Crisis)

Thyroid storm is an acute, life-threatening hypermetabolic crisis triggered by surgical stress, trauma, infection, or emergency surgery in undiagnosed or inadequately treated hyperthyroidism (Graves' disease, toxic multinodular goiter).

• Clinical Presentation: Extreme hyperpyrexia ($> 38.5-40.0^\circ\text{C}$), severe tachycardia out of proportion to fever ($> 140\text{ bpm}$, atrial fibrillation, supraventricular tachycardias), profound hypertension followed by high-output congestive heart failure, severe agitation, delirium, diarrhea, and jaundice.
• Intraoperative Differentiation: Thyroid Storm vs. Malignant Hyperthermia (MH):

Multimodal Treatment of Thyroid Storm (The 5-Step Regimen)

                    MULTIMODAL THYROID STORM REGIMEN

   1. Step 1: Inhibit Adrenergic Surge (Beta-Blockade)
      • ESMOLOL IV infusion (short half-life, titratable) OR
      • PROPRANOLOL (1-2 mg IV q15min; blocks beta receptors AND inhibits peripheral T4 -> T3 conversion)
      │
      ▼
   2. Step 2: Inhibit New Hormone Synthesis (Thionamides)
      • PROPYLTHIOURACIL (PTU) 600-1000 mg PO/NG loading, then 200-250 mg q4h
      * (Inhibits thyroid peroxidase synthesis AND inhibits 5'-deiodinase peripheral conversion)
      │
      ▼ [MANDATORY >=1 HOUR DELAY]
   3. Step 3: Inhibit Thyroid Hormone Release (Inorganic Iodine)
      • POTASSIUM IODIDE (SSKI) 5 drops PO q6h OR Lugol's Solution 10 drops q8h
      * CRITICAL RULE: Must administer >=1 hour AFTER thionamides to prevent iodine from
        serving as substrate for new hormone synthesis (Wolff-Chaikoff effect).
      │
      ▼
   4. Step 4: Block Peripheral Conversion & Treat Relative Adrenal Insufficiency
      • HYDROCORTISONE 100 mg IV q8h OR Dexamethasone 2 mg IV q6h
      │
      ▼
   5. Step 5: Active Cooling & Supportive Care
      • Acetaminophen & cooling blankets. AVOID ASPIRIN (displaces T4/T3 from thyroid-binding globulin).

Myxedema Coma

Myxedema coma is the extreme manifestation of decompensated hypothyroidism triggered by hypothermia, infection, trauma, stroke, or administration of sedatives and anesthetics.

• Clinical Presentation: Severe hypothermia ($< 35^\circ\text{C}$), profound bradycardia, hypotension, hypoventilation with blunted hypercapnic/hypoxic ventilatory drive, hyponatremia, macroglossia, and extreme sensitivity to all anesthetic agents and opioids (prolonged recovery/apnea).
• Management: Immediate IV Levothyroxine (T4) ($200-400\ \mu\text{g}$ IV loading over 30 min, then $50-100\ \mu\text{g}$ daily) $\pm$ IV Liothyronine (T3) ($5-20\ \mu\text{g}$ IV). Mandatory: Administer stress-dose Hydrocortisone 100 mg IV prior to or with thyroid hormone to prevent precipitating acute adrenal crisis due to accelerated cortisol metabolism. Slow, passive external rewarming and cautious fluid restriction for hyponatremia.

---

3. Adrenal Insufficiency & Perioperative Stress-Dose Steroids

HPA Axis Suppression & Adrenal Crisis

Exogenous corticosteroid administration suppresses the hypothalamic-pituitary-adrenal (HPA) axis via negative feedback on CRH and ACTH secretion. Under surgical stress, inability to mount an endogenous cortisol surge causes Acute Adrenal Crisis (refractory vasodilation, profound hypotension unresponsive to fluids and alpha-agonists, hyponatremia, hyperkalemia, and hypoglycemia).

ASSESSMENT OF HPA AXIS SUPPRESSION RISK:
• HIGH RISK (Suppressed): >20 mg/day Prednisone (or equivalent) for >3 weeks in the past year → REQUIRES STRESS DOSING
• LOW RISK (Not Suppressed): <5 mg/day Prednisone morning dose for any duration → NO STRESS DOSE (take usual morning dose)
• INTERMEDIATE RISK: 5 to 20 mg/day Prednisone for >3 weeks → Assess clinically or perform ACTH Stimulation Test

Perioperative Steroid Dosing Guidelines

---

4. Pheochromocytoma: Alpha-Before-Beta Blockade & Hemodynamic Crises

Pheochromocytoma is a rare, vascular neuroendocrine tumor originating from chromaffin cells of the adrenal medulla (85%) or extra-adrenal paraganglia (15%). It secretes excessive amounts of catecholamines (Norepinephrine > Epinephrine > Dopamine).

Preoperative Optimization: The Roizen Criteria

Patients with pheochromocytoma suffer from chronic, intense arteriolar and venous constriction leading to severe hypertension and contracted intravascular blood volume. Preoperative medical preparation requires a minimum of 10 to 14 days of pharmacologic stabilization:

                  THE CARDINAL RULE OF PHEOCHROMOCYTOMA

   1. Step 1: ALPHA-ADRENERGIC BLOCKADE FIRST (10 - 14 Days Pre-Op)
      • PHENOXYBENZAMINE (non-competitive, irreversible alpha-1 and alpha-2 blocker; 10 mg PO BID,
        titrated up to 40-100 mg/day) OR selective alpha-1 blockers (Doxazosin, Prazosin).
      * Relaxes peripheral vascular beds, normalizes blood pressure, and allows vascular refilling.
      │
      ▼
   2. Step 2: EXPAND INTRAVASCULAR VOLUME
      • Liberalize oral sodium chloride and fluid intake (IV crystalloids) to treat contracted plasma volume.
      │
      ▼
   3. Step 3: BETA-ADRENERGIC BLOCKADE SECOND (2 - 3 Days Pre-Op ONLY)
      • Initiate beta-blockers (Metoprolol, Propranolol) ONLY AFTER adequate alpha-blockade is established.
      • Indicated to control reflex tachycardia induced by alpha-2 blockade or epinephrine-secreting tumors.

The Deadly NCE Trap — Beta-Blockade Without Prior Alpha-Blockade: If a beta-blocker is administered alone or before adequate alpha-blockade, it blocks beta-2 mediated vasodilation in skeletal muscle vascular beds while leaving intense alpha-1 mediated vasoconstriction completely unopposed. This precipitates catastrophic hypertensive crisis, acute left ventricular failure, pulmonary edema, myocardial infarction, and intracranial hemorrhage.

Intraoperative Hemodynamics: Two Distinct Crisis Phases

1. Phase 1: Tumor Manipulation & Induction (Hypertensive Crisis):
   • Direct surgical handling or pneumoperitoneum triggers massive catecholamine dumping.
   • Treatment: Rapidly titratable, short-acting IV vasodilators:
     • Sodium Nitroprusside (SNP) (0.5 to 5.0 $\mu\text{g/kg/min}$): Direct nitric oxide donor, balanced arteriolar and venous dilator.
     • Phentolamine (1 to 5 mg IV boluses): Short-acting competitive alpha-1/alpha-2 antagonist.
     • Nicardipine / Clevidipine: Dihydropyridine calcium channel blockers.
     • Magnesium Sulfate (2 to 4 g IV): Inhibits catecholamine release from chromaffin granules and blocks vascular calcium channels.
2. Phase 2: Tumor Vein Ligation & Post-Resection (Profound Vasoplegia & Hypotension):
   • Abrupt removal of circulating catecholamines combined with chronically down-regulated adrenergic receptors and residual long-acting phenoxybenzamine alpha-blockade causes sudden circulatory collapse.
   • Treatment: Aggressive crystalloid/colloid volume expansion; Vasopressin (1 to 2 unit IV bolus, then 0.01-0.04 units/min infusion; acts on V1 receptors independent of down-regulated adrenergic pathways); Norepinephrine infusion.
   • Postoperative Rebound Hypoglycemia: Sudden loss of catecholamine-induced beta-cell suppression triggers a surge in insulin release. Monitor blood glucose closely in the PACU.

---

5. Coagulation Cascade, Platelet Function & Point-of-Care Hemostasis

                           THE CELL-BASED COAGULATION MODEL

   1. INITIATION (Tissue Factor-Bearing Cell)
      • Vascular Injury exposes subendothelial TISSUE FACTOR (TF)
      • TF binds circulating FACTOR VIIa
      • TF:VIIa complex activates Factor IX → IXa and Factor X → Xa
      • Factor Xa combines with Factor Va on cell surface to generate a small priming amount of THROMBIN (IIa)
                                    │
                                    ▼
   2. AMPLIFICATION (Platelet Surface)
      • Small amounts of Thrombin prime and activate resting PLATELETS
      • Thrombin activates Factor V → Va, Factor VIII → VIIIa (releasing it from vWF), and Factor XI → XIa
      • Platelet degranulation exposes membrane acidic phospholipids (phosphatidylserine)
                                    │
                                    ▼
   3. PROPAGATION (Activated Platelet Membrane)
      • TENASE COMPLEX: Factor IXa + Factor VIIIa + Ca2+ + Phospholipid → Generates massive FACTOR Xa
      • PROTHROMBINASE COMPLEX: Factor Xa + Factor Va + Ca2+ + Phospholipid → Catalyzes "THROMBIN BURST"
      • Thrombin converts FIBRINOGEN (Factor I) → FIBRIN MONOMERS (Factor Ia)
      • Factor XIIIa cross-links fibrin monomers into an insoluble, stable fibrin clot network

Coagulation Cascade Pathways & Monitoring

Platelet Activation & Receptor Targets

1. Adhesion: Platelet surface Glycoprotein Ib-IX-V (GP Ib) binds subendothelial von Willebrand Factor (vWF) anchored to exposed collagen.
2. Activation: Thrombin, ADP (acting on P2Y12 receptors), and Thromboxane A2 (TXA2, synthesized via COX-1) stimulate intracellular calcium release, shape change, and granule exocytosis.
3. Aggregation: Inside-out signaling transforms the Glycoprotein IIb/IIIa (GP IIb/IIIa) receptor into a high-affinity state that binds bivalent Fibrinogen (and vWF), cross-linking adjacent platelets into the primary hemostatic plug.
   • Antiplatelet Targets: Aspirin (irreversibly acetylates COX-1, halting TXA2 for platelet lifespan ~8-10 days); P2Y12 Inhibitors (Clopidogrel, Prasugrel, Ticagrelor); GP IIb/IIIa Inhibitors (Abciximab, Eptifibatide, Tirofiban).

---

6. Heparin-Induced Thrombocytopenia (Type II HIT)

Type II HIT is a life-threatening, immune-mediated adverse reaction occurring in 1% to 5% of patients exposed to unfractionated heparin (and $<1%$ with low-molecular-weight heparin).

                               TYPE II HIT IMMUNE CASCADE

   Heparin binds positively-charged Platelet Factor 4 (PF4) released from platelet alpha-granules
                                           │
                                           ▼
   Formation of immunogenic Heparin-PF4 Macromolecular Complexes
                                           │
                                           ▼
   Patient produces IgG Autoantibodies against the Heparin-PF4 complex
                                           │
                                           ▼
   IgG-Heparin-PF4 immune complexes bind platelet FcγRIIa receptors
                                           │
                                           ▼
   Massive Cross-Linking of FcγRIIa → Explosive Platelet Activation & Degranulation
                                           │
                                           ▼
   Generation of Platelet Microparticles & Procoagulant Thrombin Burst
                                           │
       ┌───────────────────────────────────┴───────────────────────────────────┐
       ▼                                                                       ▼
Platelet Consumption & Clearance                               Severe Thrombotic Complications
(Thrombocytopenia: >50% drop, 20-100k)                         • Deep Vein Thrombosis & Pulmonary Embolism
                                                               • Arterial Thrombosis (Limb ischemia, Stroke, MI)
                                                               • Skin necrosis at heparin injection sites

Clinical Evaluation: The 4Ts Score & Diagnostic Workflow

• Score Interpretation: 0-3 = Low probability; 4-5 = Intermediate probability; 6-8 = High probability.
• Laboratory Confirmation: Initial screening by Anti-PF4/Heparin ELISA (high sensitivity, low specificity); confirmatory gold-standard functional assay is the Serotonin Release Assay (SRA) (detects donor platelet activation in presence of patient serum and heparin).

Management of Confirmed or Suspected HIT

1. IMMEDIATELY STOP ALL HEPARIN SOURCES: Discontinue UFH, LMWH, heparin flushes, heparin-bonded arterial/CVP catheters, and heparin-coated bypass circuits.
2. DO NOT TRANSFUSE PLATELETS: Platelet transfusion is strictly contraindicated because transfused platelets bind circulating immune complexes and "fuel the thrombotic fire", triggering acute catastrophic thrombosis (unless active life-threatening hemorrhage is occurring).
3. INITIATE A NON-HEPARIN DIRECT THROMBIN INHIBITOR (DTI):
   • Argatroban: IV continuous infusion titrated to target aPTT 1.5 to 3.0 times baseline (typically 50-70 seconds). Metabolized solely by the liver (safe in severe renal failure; dose reduction required in hepatic impairment).
   • Bivalirudin: IV continuous infusion (partially enzymatically cleaved by thrombin and 20% renal elimination; preferred DTI for cardiac surgery / CPB and coronary intervention in patients with acute HIT).
4. WARFARIN TIMING RULE: Do NOT administer Warfarin until platelet count has fully recovered to $\ge 150,000/\mu\text{L}$ AND therapeutic DTI anticoagulation is established. Starting Warfarin during acute HIT causes rapid depletion of short-half-life Protein C before factors II/X decline, precipitating widespread microvascular thrombosis, venous limb gangrene, and warfarin-induced skin necrosis.

---

7. Perioperative Anaphylaxis vs. Anaphylactoid Reactions

                           IMMUNOLOGIC MECHANISMS OF MAST CELL ACTIVATION

   IG-E MEDIATED ANAPHYLAXIS (Type I Hypersensitivity)    NON-IGE / ANAPHYLACTOID (Direct Activation)
   • Requires PRIOR SENSITIZATION                        • NO prior sensitization required
   • Allergen cross-links specific IgE antibodies        • Direct chemical activation of MRGPRX2
     bound to high-affinity FcεRI receptors on             receptors or complement activation (C3a, C5a)
     Tissue Mast Cells and Circulating Basophils         • Direct histamine release
   • Triggers immediate, explosive degranulation         • Rate-dependent (e.g., Vancomycin flushing)
                           │                                             │
                           └──────────────────────┬──────────────────────┘
                                                  ▼
                                     MASSIVE CHEMICAL MEDIATOR RELEASE
                     • Histamine (H1: bronchospasm, capillary permeability; H2: vasodilation, inotropy)
                     • Tryptase (mast cell specific neutral protease)
                     • Leukotrienes (LTC4, LTD4, LTE4: potent bronchoconstrictors)
                     • Prostaglandin D2 (PGD2: peripheral vasodilation & coronary vasoconstriction)
                     • Platelet-Activating Factor (PAF)

Common Perioperative Trigger Agents

• Neuromuscular Blocking Agents (50% to 60% of cases): Most frequent cause of IgE-mediated perioperative anaphylaxis. Succinylcholine and Rocuronium have the highest incidence (cross-reactivity occurs due to shared substituted quaternary ammonium epitopes found in cosmetics, hair conditioners, and detergents).
• Antibiotics (15% to 20% of cases): Beta-lactams (Penicillins, Cefazolin). Cross-reactivity between penicillin and 1st-generation cephalosporins is ~1-3%; cross-reactivity with 2nd/3rd/4th generation cephalosporins (e.g., Cefepime, Ceftriaxone) sharing dissimilar R1 side chains is $<1%$.
• Latex (10% to 15% of cases): High-risk groups include spina bifida/myelomeningocele patients, healthcare workers, chronic urinary catheterization, and patients with tropical fruit allergies (banana, avocado, kiwi, chestnut).
• Other Culprits: Chlorhexidine skin prep, Sugammadex, Blood products, Protamine (risk increased in patients with previous NPH insulin use, vasectomy, or fish allergies), and direct non-IgE histamine releasers (Vancomycin, Morphine, Atracurium).

Clinical Manifestations Under General Anesthesia

Under general anesthesia, conscious warning symptoms (pruritus, dyspnea, tingling, substernal tightness) are entirely absent. The presentation is dominated by sudden, life-threatening cardiorespiratory collapse:

1. Severe Hypotension & Cardiovascular Collapse (Most Common Sign, ~90%): Sudden vasoplegia and massive capillary permeability leading to extravasation of up to 35% to 50% of intravascular fluid into the third space within 10 minutes.
2. Severe Bronchospasm & High Peak Pressures (~45%): Marked increase in peak inspiratory pressure (PIP), loss of tidal volume, or complete "flat line" capnography tracing due to absent expiratory gas flow.
3. Cutaneous Signs (Urticaria, Erythema, Angioedema): Present in ~70% of cases but frequently concealed beneath surgical drapes.

Emergency Anaphylaxis Management Protocol

                    IMMEDIATE RESCUE PROTOCOL FOR ANAPHYLAXIS

   1. STOP SUSPECTED TRIGGERING AGENT IMMEDIATELY & Call for Help
   2. DISCONTINUE VOLATILE ANESTHETICS (Eliminate vasodilation/myocardial depression; give 100% FiO2)
   3. FIRST-LINE DRUG OF CHOICE: EPINEPHRINE (Administer immediately!)
      • Mild-to-Moderate Hypotension: IV Bolus 10 to 20 µg (0.1-0.2 mL of 1:10,000 diluted or 10-20 µg/mL)
      • Severe Cardiovascular Collapse: IV Bolus 100 to 1,000 µg (0.1-1.0 mg)
      • Refractory / Ongoing Shock: Continuous Infusion 0.05 to 0.5 µg/kg/min (2 to 20 µg/min)
      * Alpha-1 restores SVR & perfusion pressure; Beta-1 restores inotropy; Beta-2 elevates intracellular
        cAMP in mast cells, HALTING FURTHER DEGRANULATION and relieving bronchospasm.
   4. AGGRESSIVE VOLUME RESUSCITATION: IV Crystalloid 20 to 40 mL/kg (1 to 4 Liters) rapid pressure bag
   5. SECOND-LINE DRUGS FOR REFRACTORY VASOPLEGIA (Especially in patients on Beta-Blockers):
      • GLUCAGON: 1 to 5 mg IV over 5 min, then 1-5 mg/hr infusion (activates adenylate cyclase bypassing beta-receptors)
      • VASOPRESSIN: 1 to 2 units IV bolus, then 0.01-0.04 units/min
      • METHYLENE BLUE: 1.5 to 2.0 mg/kg IV over 20 min (inhibits inducible nitric oxide synthase & guanylate cyclase)
   6. SECONDARY ADJUNCTS (Do NOT delay epinephrine):
      • Diphenhydramine (25-50 mg IV) + Famotidine (20 mg IV)
      • Hydrocortisone (100-200 mg IV) or Methylprednisolone (1-2 mg/kg IV) to prevent biphasic reactions
      • Inhaled Albuterol for persistent bronchospasm

Laboratory Confirmation: Serum Tryptase

• Serum Tryptase: The definitive laboratory biomarker confirming mast cell degranulation.
• Sampling Timing: Draw acute serum sample within 1 to 2 hours of the initial clinical reaction (tryptase levels peak at 1-2 hours, with an elimination half-life of ~2 hours). Obtain a baseline serum tryptase level at $\ge 24\text{ hours}$ post-event.
• Diagnostic Consensus Criterion:

$\text{Peak Serum Tryptase} > (1.2 \times [\text{Baseline Tryptase}] + 2.0\ \mu\text{g/L})$